Copyright
©2014 Baishideng Publishing Group Inc.
World J Hematol. Aug 6, 2014; 3(3): 71-84
Published online Aug 6, 2014. doi: 10.5315/wjh.v3.i3.71
Published online Aug 6, 2014. doi: 10.5315/wjh.v3.i3.71
Disease | Molecular abnormalities(chromosome location) |
CTL molecule dysfunction | |
Pore formation | |
FHL2 | Perforin (10q21-2) |
Vesicle priming fusion | |
FHL3 | Munc13-4/Unc 13D (17q25) |
FHL4 | Syntaxin 11 (6q24) |
FHL5 | STXBP2/Munc18-2 (19p13) |
Vesicle docking/trafficking | |
Chediak-Higashi syndrome | LYST (1q42.1-42.2) |
Griscelli syndrome, type 2 | Rab27a (15q21) |
Hermansky-Pudlak syndrome II | AP-3 (3q24) |
EBV-driven | |
XLP1 | SAP/SH2D1A (Xq25) |
XLP2 (XIAP) | BIRC4 (Xq24-25) |
ITK deficiency1 | ITK (5q34) |
CD27 deficiency1 | CD27 (12p13) |
XMEN1 | MAGT1 (Xq21.1) |
The diagnosis of HLH can be established if one of either (1) or (2) below is fulfilled | |
(1) A molecular diagnosis consistent with HLH | |
(2) Clinical diagnostic criteria fulfilled for 5 out of the 8 criteria below | |
Clinical criteria | 1 fever |
2 splenomegaly | |
Routine laboratory criteria | 3 bicytopenia (Hb < 90 g/L, |
platelets < 100 × 109/L, neutrophils < 1.0 × 109/L) | |
4 Hypertriglyceridemia (> 3.0 mmol/L) | |
and/or hypofibrinogenemia (< 1.5 g/L) | |
Specific histopathological/marker criteria | 5 hemophagocytosis |
6 low or absent NK cell activity | |
7 hyperferritinemia (> 500 μg/L) | |
8 hyper-sIL-2R-nemia (> 2400 U/mL) |
Persistent increase of cell-free EBV genome copies |
Chromosome abnormality |
Correlation with chronic active EBV infection (CAEBV)1 |
In association with primary HLH |
Severe organ dysfunction, such as renal failure, CNS hemorrhage |
Choice of treatment, such as timing of etoposide use, HSCT |
- Citation: Imashuku S. Hemophagocytic lymphohistiocytosis: Recent progress in the pathogenesis, diagnosis and treatment. World J Hematol 2014; 3(3): 71-84
- URL: https://www.wjgnet.com/2218-6204/full/v3/i3/71.htm
- DOI: https://dx.doi.org/10.5315/wjh.v3.i3.71